OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback